Emergent BioSolutions (EBS) Debt to Equity: 2010-2025
Historic Debt to Equity for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $1.14.
- Emergent BioSolutions' Debt to Equity fell 12.55% to $1.14 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.14, marking a year-over-year decrease of 12.55%. This contributed to the annual value of $1.37 for FY2024, which is 99.91% up from last year.
- As of Q3 2025, Emergent BioSolutions' Debt to Equity stood at $1.14, which was down 8.60% from $1.25 recorded in Q2 2025.
- Over the past 5 years, Emergent BioSolutions' Debt to Equity peaked at $1.37 during Q4 2024, and registered a low of $0.32 during Q4 2022.
- In the last 3 years, Emergent BioSolutions' Debt to Equity had a median value of $1.14 in 2025 and averaged $0.93.
- As far as peak fluctuations go, Emergent BioSolutions' Debt to Equity crashed by 35.65% in 2022, and later skyrocketed by 147.36% in 2024.
- Emergent BioSolutions' Debt to Equity (Quarterly) stood at $0.50 in 2021, then plummeted by 35.65% to $0.32 in 2022, then soared by 112.77% to $0.69 in 2023, then spiked by 99.91% to $1.37 in 2024, then declined by 12.55% to $1.14 in 2025.
- Its last three reported values are $1.14 in Q3 2025, $1.25 for Q2 2025, and $1.20 during Q1 2025.